Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow much weight loss in a month with Mounjaro? In clinical trials, people lost roughly 1–2% of body weight per month on average during the early stages, with the rate shifting as doses increase — but individual results vary considerably and depend on dose, diet, activity and biology. Mounjaro (tirzepatide) is a prescription-only medicine: a GPhC-registered prescriber assesses your suitability before any treatment begins, and results described here come from published trial data, not guarantees.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks is some version of this: 'Will I see results in the first month?' The honest answer is: probably some, but the first four weeks are not the most dramatic. Treatment starts at the 2.5 mg starter dose, which exists to let your body adjust rather than to drive significant weight loss. The clinical trials that support Mounjaro's UK licence showed average body-weight reductions of around 20–21% over 72 weeks at the highest dose, published in the SURMOUNT-1 trial in the New England Journal of Medicine. Spread that across 18 months and you get roughly 1–1.5% per month on average, though in practice the rate tends to accelerate once doses increase and plateau as you approach a maintenance weight.
Most people notice appetite changes within the first two weeks. The scales, however, tend to reflect it a little later. Early losses of 1–3 kg in the opening month are common, but some people see more and some see less, neither outcome signals that the medicine is or isn't working. The first month on Mounjaro is better measured by tolerability than by kilograms. If you want a closer look at how much weight loss a Mounjaro injection typically produces in a month, including what varies between people and doses, we cover that in detail. A more detailed breakdown of how weight loss tends to progress across the full titration schedule is on our month-by-month progress page.
UK private Mounjaro prices have shifted substantially. Eli Lilly raised the list price of its highest-dose pen from around £122 to around £330 per four-week pen from 1 September 2025, and typical private prices since then range roughly £149–£375 per month depending on dose and provider, as widely reported following Lilly's announcement. Those figures are genuinely wide. Understanding why helps.
Some headline prices are for the pen alone. The consultation fee (sometimes £30–£80), the prescription charge and delivery can sit on top, meaning a seemingly low monthly figure climbs once you add everything together. Other providers bundle some of these but charge for aftercare separately or ask for a subscription you can cancel only after a set period. The full Mounjaro pricing picture covers this in more detail, including what to check before committing to any private provider. You can also review the overall cost of Mounjaro weight loss treatment to see how pricing relates to the dose you're on.
For context on what this medicine is and how it works before thinking about cost at all, the Mounjaro treatment overview is a good starting point.
We don't compete on price and we don't pretend otherwise. A single transparent monthly cost at nume covers the free consultation, the prescription, the medicine itself, free next-working-day DPD delivery, and priority aftercare seven days a week. No add-ons, no subscription, no auto-renewal. Every repeat order goes back in front of a prescriber for clinical re-review before it's dispensed.
We are registered with the GPhC (premises number 9012878, verifiable on the GPhC register) and medicines move through the licensed UK supply chain. Current treatment pricing is shown on the weight-loss treatments page; we don't publish per-pen prices in our editorial content because the right dose (and therefore the right cost) is determined by a prescriber, not by a checkout page.
If you're weighing up your options across treatments more broadly, our weight-loss treatment overview explains what's licensed in the UK and how each option differs.
The evidence for how much weight loss in a month on Mounjaro comes from trials using pharmaceutical-grade, properly stored, verified medicine. Counterfeit tirzepatide pens have been seized in large quantities by the MHRA (including from an illicit manufacturing site in the UK) and have been found to contain incorrect or unknown substances. The MHRA's Yellow Card scheme is where you can report a suspect seller or a suspected adverse reaction.
A prescriber who reviews your medical history, checks your weight on a live video call, and monitors your progress between doses isn't a cost centre, it's what makes the medicine safe to take. Providers offering these medicines without clinical assessment, or with prices so far below the market rate that no consultation could plausibly be included, are a red flag rather than a bargain. Real value here is clinical rigour, genuine supply chain, and a pharmacy you can look up by registration number. That's the measure that matters.
If you'd like to understand the evidence on overall weight loss with Mounjaro in more depth, our page on how much weight loss to expect on Mounjaro covers the full picture, including what the data says about long-term outcomes.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.